Performance analysis of Acasti Pharma (GRCE)
Annual Return
Since Oct 8, 2024, GRCE has had an average annual return of -11.48%, underperforming the benchmark SPY, which returned +17.45% annual.
| 2026 | 2025 | 2024 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.77% | -7.49% | +23.84% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.91% | +18.18% | +7.93% | -51.62% | +14.74% | -11.67% | +7.04% | -29.77% | |||||
| 2025 | -11.77% | -8.18% | -24.75% | +14.46% | +6.25% | +7.10% | -2.68% | +4.84% | -1.74% | +5.97% | +0.79% | +8.80% | -7.49% |
| 2024 | +5.96% | +5% | +11.31% | +23.84% |
Drawdown analysis of Acasti Pharma (GRCE)
The maximum drawdown for the GRCE was -60.00%, occurring on Apr 7, 2025. Recovery took 242 trading sessions.
The current GRCE drawdown is -52.63%.
Since Oct 8, 2024 GRCE has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 2 times
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -60.00% | Dec 6, 2024 | 81 | Apr 7, 2025 | 242 | Mar 25, 2026 | 323 |
| -59.06% | Apr 2, 2026 | 17 | Apr 28, 2026 | Ongoing | Ongoing | Ongoing |
| -18.06% | Oct 23, 2024 | 12 | Nov 8, 2024 | 17 | Dec 4, 2024 | 29 |
| -8.60% | Mar 26, 2026 | 2 | Mar 30, 2026 | 2 | Apr 1, 2026 | 4 |
| -5.57% | Oct 10, 2024 | 7 | Oct 21, 2024 | 2 | Oct 23, 2024 | 9 |